EditCo Bio, Inc. Expands Primary Cell Portfolio with Launch of Knockout CD8+ T-cell Pools

REDWOOD CITY, Calif.–(BUSINESS WIRE)– #Tcell–EditCo Bio, Inc., a leader in genome engineering innovation, announced the expansion of its T-cell editing portfolio with the launch of Knockout CD8+ T-cell Pools. This new addition builds upon the success of their Knockout CD4+ T-cell Pools, offering researchers an advanced tool for primary T-cell editing that brings unprecedented precision and scalability to cancer and immunotherapy research. Leveraging EditCo Bio’s cutting-edge automated platform, the n
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks